Cealtech: Ready for mass production of supermaterial

The Norwegian company Cealtech will start production of graphene – a material that can be important in everything from oil and gas to electronics, solar, medicine and spacecraft.

“It sounds like a material that will be a major revolution for new material technologies in the future,” says Prime Minister of Norway, Erna Solberg.

She newly met the Norwegian company that will soon mass-produce the super material graphene – known to be the thinnest and strongest material that has been created, with the potential to revolutionize a number of industries.

After the meeting Solberg said that it is important that we are able to develop new technologies.

“Norway is a country that is very good at material technology. It has been a priority since the early 80’s.

Super material

The material with a number of unusual characteristics, one of them being that it is 200 times stronger than steel, but very flexible, was first isolated by physicists Andre Geim and Konstantin Novoselov in 2004 – with the help of a fairly common piece of tape and graphite.

The two later won the Nobel Prize in Physics for their work with graphene.

The structure of the material is only one atom thick, based on carbon-shape graphite, with qualities that allow applications that span from industries such as oil and gas to electronics, solar, medicine and spacecraft.

– It’s a supermaterial. If we can find large-volume applications for graphene at sufficiently low prices, we will enter into a new age, says Lars Helge Helvig.

He is the largest owner and Acting General Manager of the Stavanger-based company Cealtech.

Prime Minister Erna Solberg met Cealtech in Oslo last Tuesday. From right: David Boyd at Caltech University, Technical Manager Marius Andreassen Jakobsen in Cealtech and Acting General Manager in Cealtech, Lars Helge Helvig.



Cancer in the family led Bjørn Rune Gjelsten into ownership in the cancer vaccine company Ultimovacs

Dagens Næringsliv

Cancer in the family led Bjørn Rune Gjelsten into ownership in the cancer vaccine company Ultimovacs. The company is now attracting interest from “big pharma” players and the company valuation is approaching 1 billion NOK.

Bjørn Rune Gjelsten had a personal reason to go into Ultimovacs. Now, the company that develops cancer vaccine based on immunotherapy can also prove to be a very good investment.

“The reason I entered was that I had cancer in my family. My father got sick and I got in touch with an environment around the Radium Hospital, says Gjelsten, who lost his father with prostate diagnosis a couple of years ago.

The company was in an early phase and faced a capital tire. So far, Gjelsten has invested NOK 30 million.

“Although I had a personal entrance, it’s no more money than it would be okay to lose,” he says.

As the development of the vaccine goes through different phases, the value of Ultimovacs also rises. Gjelsten Holding holds 35 percent of the shares.

“Now there is interest from large industrial players from big pharma and the Norwegian investor communities.

Strengthens the immune system

By means of immunotherapy, the body will be equipped to to fight the cancer cells.

One of the unanswered questions is how the vaccine works in combination with other medications in order to attack the cancer cells. This has aroused the interest of pharmaceutical companies with well-established cancer medicine. Immunotherapy and traditional medicine can attack the cancer from two angles, so-called duo treatment.

“The traditional medicine may weaken and passivate the cancer, while immunotherapy activates the immune system so that the body may attack the cancer by itself.

A real breakthrough will be if the vaccine can be used preventively against vulnerable groups.

– US authorities are now looking into whether the vaccine can be used proactively, Gjelsten adds.

Stock exchange for similar company

Ultimovacs is compared to another fast-growing immunotherapy company, Targovax, which has already reached a face value of NOK 1.1 billion on the stock exchange. The share price of Targovax has risen 120 percent since January last year.

Jonas Einarsson, Managing Director of the Radium Hospital Research Foundation, believes the two companies have clear resemblances and confirm that immunotherapy vaccines developed in Norway have become interesting for drug giants.

– The Vaccines that these two companies develop are made on the same platform, but have different types of attacks. I have to say that the clinical results are encouraging, but it takes time. I am an optimist for both companies, says Einarsson, who is in the board of both companies.


Ultimovacs will give a presentation in the Conference Program at 37 °C,

on June 6th.

Source: http://www.dn.no/nyheter/2017/05/15/2101/Industri/kreftvaksine-kan-gi-superavkastning-for-gjelsten

Startup Competition Deadline has been extended till 21 May!

Startup Competition Deadline has been extended till 21 May!

37 ºC Life Science Technology Conference & Exhibition has a carefully crafted Program and a stimulating Exhibition. The international participants attending 37ºC represent the global life science community, who are eager to explore and engage in business opportunities.

The Official Conference Program is now online for you to view:

Register now! Special 50% discounted price for Startups! 


Under one roof, Hi-tech and Biomed join hands, and offer participants a varied and interlinked program with the participation by leaders in both fields.

The 1ST Prize for the Winner of the Startup Pitch Competition will be Private Meetings with Hadean Ventures and Glenrock Group.

10 Startup Companies will be selected to pitch for the high-profile Jury. Companies will have 5 minutes to pitch and 5 minutes for questions and answers.

We are proud to present the Startup Competition Jury:

    • Arve Grude, Senior Manager in EY
    • Henrik Lund, Chairman Oslo Cancer Cluster
    • Asaf Iram, Investment Manager at GlenRock Group
    • Kamilla Rolstad, Partner of Sund Capital
    • Walter Stockinger, Dr Managing Partner at Hadean Ventures
    • Morten Graugaard Døssing, Investment Director at Novo Seeds (TBC)
    • Sjur Svaboe, Founder and CEO of Biolink Group and Medpalett Medox (TBC)

 For more information, please contact:
General Manager
tel.: +47 940 10 236,
e-mail:  arne@exceller.no

Norway, Stavanger, aerial view Attractive hotel rates have been negotiated at the Clarion Hotel Energy, which is located ca 300 meters from the Conference Venue, which is ca 4,5 km from the charming and picturesque city center of Stavanger. You may book your hotel HERE

This is a great opportunity to explore the Fjords in the region, which are easily reachable. For more information on our website, CLICK HERE


Med-Tech Planet: Mapping Medical Device Startups Across The Globe

The US accounts for 77% of global medical device deal share while Israel and the United Kingdom are tied for second.

Global funding to private medical device companies rose in 2016, reaching nearly $4B in 2016 across 479 deals. The United States receives a lot of attention when it comes to funding medical device startups, but private companies around the world are raising significant rounds.

For example, this year has seen rounds to Atlas Genetics in the United Kingdom, MedLumics in Spain, and Breath Therapeutics in Germany. In addition, Israel, one of the most active hubs of medical device activity, saw medical technology giant Becton Dickinson take a $250M corporate majority stake in Caesarea Medical Electronics, a manufacturer of infusion and syringe pump systems.

Below, we used CB Insights data to track funding and deal flow to companies operating in the US and internationally. We also created a map showcasing the top 3 most well-funded medical device startups in countries with at least 10 private medical device companies. Scroll down to see the map and a full list of startups included in the graphic.

Check out the program and Keynote speakers of the 37 °C event 6-7 June!

Register here!



hannoverimpuls – your gateway to the 3rd biggest market in the world, Germany

hannoverimpuls, represented by Katharina Hanske, will exhibit at 37 °C. Germany is the 3rd biggest healthcare market in the world. hannoverimpuls offers a range of attractive services to support the expansion projects of companies. Our target: avoid risks upon entry to the market, and provide our clients with optimal individual and unbureaucratic relocation support. To put it another way: our job consists of simplifying as much as possible the establishment of your successful business in Hannover.

Register for 37 °C today: https://37degreescelsius.net

Check out hannoverimpuls, here.

The German, Danish and Norwegian perspectives on clinical trials. Panel on 37 °C Life Science Technology Conference and Exhibition 6-7 June Stavanger

Screen Shot 2017-05-09 at 16.39.43.png

Anne Kjersti Fahlvik, Heiko von der Leyen, Britta Smedegaard Andersen, Birgitta Tunning

The panel will consist of Heiko von der Leyen (MD CEO of Hannover Clinical Trial Center), Britta Smedegaard Andersen (Project Director of the Danish NEXT project) and Anne Kjersti Fahlvik (Executive Director of the Division for Innovation at the Research Council of Norway). And be moderated by Birgitta Tunning (eHealth Unit Leader Nordics in IBM).

The panel discussion will cover the clinical trials aspects of market entry, comparing modus operandi in different countries Impact of new EU regulations; The role that clinical studies plays in sustaining and building industry; Impact of digital technology, AI and personalised medicine.

To Register, click here: https://37degreescelsius.net/registration/

We are looking forward to seeing you on 37 °C in June!

37 ºC Keynote Speaker, Ole Petter Ottersen, yesterday was appointed by the Swedish Government to be the new Rector at Karolinska Institute in Stockholm

Ole Petter Ottersen named Vice-Chancellor at Karolinska Institutet

Published 2017-04-27 12:55. Updated 2017-04-27 13:26Denna sida på svenska

On 27 April, the government decided to appoint Ole Petter Ottersen Vice-Chancellor at Karolinska Institutet. He will take office on 1 August 2017.

“I am honored to be appointed rector of Karolinska Institutet – a university that I have looked up to throughout my career. It is a great privilege to be able to lead such a prominent institution,” Ole Petter Ottersen says.

“I look forward to getting started and to work together with KI’s many talented researchers, board members, staff, students and multiple collaborative partners nationally and internationally. Together we will strengthen public trust and internal enthusiasm and pride,” he continues.

Ole Petter Ottersen is currently rector of the University of Oslo, where he has held several leading positions, including dean of research for the medical faculty. He is also a professor of medicine.

The appointment as vice-chancellor of the Karolinska Institute applies from 1 August 2017 until 28 February 2022.


Ottersen ny rektor på Karolinska Institutet

Rektor. Den svenske regjeringen har torsdag 27. april utnevnt Ole Petter Ottersen til ny rektor for Karolinska Institutet.

Den svenske regjeringen har fulgt oppfordringen fra Karolinska Institutet (KI) og utnevnt rektor for Universitet i Oslo, Ole Petter Ottersen som ny rektor på KI.

— Jeg er beæret over å ha blitt utnevnt til rektor på Karolinska Institutet, ett universitet jeg har sett opp til i hele mine karriere, sier Ottersen i en pressemelding på ki.se.

— Det er et stort privilegium å få lede en så fremragende institusjon, legger Ottersen til.

Ser fram til å komme i gang

Han sier også at han ser fram til å komme i gang med jobben som rektor.

— Sammen med KIs mange dyktige forskere, ledere, studenter og samarbeidspartnere nasjonalt og internasjonalt, skal vi styrke allmenhetens tillit og den interne entusiasmen og stolthet, sier Ottersen.

Ottersen skal tiltre 1. august 2017 og er ansatt til og med 28. februar 2022.

— Jeg ønsker Ole Petter Ottersen lykke till med sitt oppdrag som rektor for Karolinska Institutet og ser fram til ett konstruktivt samarbeide, sier Helene Hellmark Knutsson, minister for høyere utdanning og forskning, i en pressemelding fra den svenske regjeringen.

Plattformen til Ottersen

I plattformen Ottersen presenterte for den såkalte «hörandeforsamlingen» ved KI skriver han den krisen KI har vært gjennom også gir mulighet for universitet til å heve seg opp til et nytt nivå.

— Karolinska Institutet må fortsatt arbeide for internasjonal eksellens innen forskning og utdanning, men satsingen og kravet til eksellens må hele tiden balanseres med et like stort krav til verdigrunnlag, etikk og arbeidskultur. Slik jeg ser det, er eksellens og arbeidskultur synergistisk avhengig av hverandre, skriver Ottersen.

Må bli mer robust

Ottersen skriver også at krisen som Karolinska Institutet har gjennomgått, krever at man gjennomlyser hele organisasjonen og gjør nødvendige endringer slik at den vil fremstå som mer robust og motstandsdyktig mot nye kriser.

— Dette er fullt ut mulig uten at det skal gå på bekostning av det som er selve grunnmuren i et universitet: Den akademiske friheten. Endringene må motiveres og forankres, og de må oppleves som viktig for både eksellens og arbeidskultur.

Ottersen skriver også at studentene er veldig viktig for ham og at en av hans første handlinger blir å besøke de 22 forskjellige institusjonene for å lære organisasjonen å kjenne og for å danne meg et godt bilde av det som nå oppleves som de største utfordringene.

Vil omorganisere

Ottersen slår også fast at det er nødvendig å diskutere organiseringen av Karolinska Institutet.

— Så vidt jeg forstår er organiseringen nærmest uendret siden 1993. Rammene for organisasjonens drift har endret seg mye siden den gang. Digitalisering, nye teknologier og større krav til økonomi og administrative prosesser betinger at man ser på organisasjonskartet på nytt. Dette er – etter mitt syn – også nødvendig for å kunne frigjøre mer tid til strategi og langsiktig utviklingsarbeid for rektor og universitetsledelsen, skriver han og legger til:

— Jeg vil foreslå at det i tillegg til det nye etikkrådet ved Karolinska Institutet også opprettes vitenskapsombud. Slike ombud kan være et lavterskeltilbud til forskere der det er oppstått uenighet rundt forfatterskap, intellectual property, eller lignende. Ombudene kan fange opp og adjudikere i tvister før de eskalerer og må håndteres på høyere nivå i organisasjonen eller av eksternt utvalg.

Skapte rektorbråk

Veien fram mot rektorstolen på KI har ikke gått upåaktet hen. Siden i november i fjor har det vært klart at Ottersen var aktuell for to ulike rektorstillinger i Sverige, både KI der han endte opp, men han var også aktuell for universitet i Gøteborg.

Ikke bare aktuell, men han skal først ha takket først ja etter å ha blitt anbefalt av den såkalte hørende forsamlingen ved Göteborgs universitet.

Etter noen få dager trakk han seg, fordi KIs ledelse sterkt ønsket ham. Dette satte sinnene i kok i Gøteborg, her følte mange seg holdt for narr av Ottersen.

Ottersen sin motkandidat, Eva Wiberg, takket ja til jobben, og for en uke siden ble hun også utnevnt av den svenske regjeringen som rektor for Göteborgs universitet.

Styreleder i Gøteborg var skuffet

— Styret hadde to meget sterke kandidater å ta stilling til. Hadde vi visst at en av dem var aktuell i en annen rekrutteringsprosess hadde vår beslutning blitt en annen, sa Cecilia Schelin Seidegård, i en pressemelding fra Göteborgs universitet i januar tidligere i år.

Allerede i november skrev Khrono at Ottersen var aktuell både ved Karolinska Institutet og i Gøteborg.

— Det er lenge siden november. Ottersen har stått foran «hörandeforsamlingen» ved universitetet vårt og sagt at får han jobben i Gøteborg så tar han den. Det hørte vi alle sammen, sa Seidegård i januar, og hun fortalte videre:

— Det var tirsdag i forrige uke at jeg fikk høre at det var satt i gang en «snabbprosess» med rekruttering på Karolinska Institutet (KI) og at Ottersen var aktuell der.

— Så avklaringen fra Ottersen kommer på oppfordring fra dere?

— Absolutt. Jeg snakket med ham fredag og fikk det da muntlig at han ikke var aktuell, og så kom det skriftlig søndag, svarte styrelederen i Gøteborg.

— Kom dette overraskende på dere?

— Det kom meget overraskende, og det er utrolig kjedelig for oss. Vi mener virkelig det vi har skrevet i pressemeldingen. Vi hadde to veldig gode kandidater, hadde vi visst dette, hadde vi valgt Eva Wiberg med en gang, sa Seidegård i januar.


Check out the program and Keynote speakers of the event!


Source: https://khrono.no/campus-samfunn/2017/04/ottersen-ny-rektor-pa-karolinska-institutet